pneumonia
death
occur
children
year
old
figur
larg
improv
sinc
eighti
childhood
respiratori
tract
infect
account
million
childhood
death
per
year
epidemiolog
childhood
pneumonia
vari
wide
differ
region
world
relat
preval
risk
factor
caus
pathogen
pneumonia
episod
occur
southeast
asia
africa
importantli
subsaharan
africa
account
pneumonia
death
despit
constitut
world
popul
lowand
middleincom
countri
lmic
incid
reduc
last
decad
episod
per
child
year
figur
show
worldwid
incid
pneumonia
children
year
old
increas
hygien
antibiot
therapi
vaccin
streptococcu
pneumonia
sp
pneumococc
conjug
vaccin
pcv
haemophilu
influenza
type
b
hib
larg
decreas
morbid
children
develop
world
especi
contribut
hib
cap
fall
quit
rapidli
widespread
vaccin
major
lmic
countri
vaccin
hib
countri
introduc
hibvaccin
countri
pcv
estim
reduct
hiband
pcv
radiolog
confirm
rc
pneumonia
respect
recent
asian
studi
note
declin
rccap
young
children
hib
vaccin
howev
hivepidem
increas
incid
childhood
cap
larg
burden
pneumonia
child
health
mortal
optim
manag
pneumonia
hot
topic
optim
manag
compris
good
access
health
care
servic
adequ
diagnosi
ration
easili
avail
inexpens
antimicrobi
therapi
lead
fast
resolut
symptom
major
children
pneumonia
resist
must
prevent
restrict
use
gener
use
narrowspectrum
antibiot
review
describ
avail
evid
etiolog
manag
cap
otherwis
healthi
children
beyond
neonat
period
microbiolog
method
studi
etiolog
cultur
polymeras
chain
reaction
pcr
direct
immunofluoresc
antigen
test
pair
serolog
upper
respiratori
tract
urt
sampl
nasoor
oropharyng
swab
often
use
surrog
marker
lower
respiratori
tract
lrt
sputum
pleural
fluid
lung
tap
bronchoalvealor
lavag
fluid
biopsi
posit
predict
valu
specif
urt
sampl
might
limit
lrt
sinc
mani
potenti
pathogen
organ
also
colon
urt
blood
cultur
rare
add
diagnosi
cap
might
lead
prolong
hospit
target
approach
identifi
patient
cap
risk
bacteraemia
might
aid
yield
posit
blood
cultur
prevaccin
era
pretreat
children
lmic
bacteria
detect
lung
aspir
mainli
sp
hib
virus
present
postmortem
studi
lung
tissu
sampl
mexican
children
younger
year
die
pneumonia
show
respiratori
syncyti
viru
rsv
patient
bacteri
pcr
postmortem
store
chines
lung
tissu
sampl
period
show
hib
caus
pathogen
fatal
cap
children
recent
systemat
review
seri
incid
pathogen
childhood
cap
found
hib
respons
fatal
case
adjust
hib
vaccin
data
avail
futur
perch
pneumonia
etiolog
research
child
health
project
studi
postmortem
sampl
combin
antemortum
sampl
modern
techniqu
defin
caus
death
children
pneumonia
vaccineera
recent
childhood
empyema
studi
pcr
aid
yield
pathogen
major
sever
pneumonia
case
still
caus
sp
nonvaccin
type
follow
pyogen
howev
concomit
viral
infect
investig
among
case
empyema
lmic
sp
hib
aureu
play
major
role
hospit
preschool
kenyan
children
cap
underw
induc
sputum
cultur
andor
pcr
blood
cultur
nasopharyng
pcr
evid
bacteri
infect
viral
mix
viralbacteri
pathogen
found
type
studi
perform
new
caledonia
show
probabl
pathogen
hospit
case
virus
rsv
hrv
common
bacteri
pathogen
induc
sputum
sampl
hospit
children
year
radiolog
confirm
rc
cap
show
pathogen
patient
use
viral
antigen
detect
pcr
cultur
major
children
viralbacteri
coinfect
follow
bacteri
infect
viral
infect
human
rhinoviru
hrv
sp
common
coinfect
detect
viral
pathogen
often
detect
postpcv
era
compar
prepcv
era
british
children
rccap
mainli
new
techniqu
blood
nasopharyng
swab
pcr
bacteri
infect
rate
mainli
sp
similar
preand
post
era
pavia
review
etiolog
recent
studi
children
hospit
cap
tabl
studi
use
nasopharyng
multiplex
pcr
cultur
averag
pathogen
detect
rate
sampl
one
bacteria
found
virus
detect
coinfect
hrv
rsv
major
contributor
although
method
slightli
differ
figur
quit
compar
studi
also
atyp
bacteria
found
preschool
children
larg
usa
studi
conduct
hospit
children
year
rccap
show
pathogen
pcr
urt
swab
serolog
blood
cultur
children
mostli
singl
multipl
virus
major
rsv
hrv
follow
bacteria
coinfect
howev
children
comorbid
mainli
asthma
thu
popul
fulli
compar
previous
healthi
children
might
also
explain
low
incid
bacteri
infect
chines
serolog
studi
aim
determin
viral
atyp
bacteri
respiratori
infect
hospit
children
mycoplasma
pneumonia
found
main
caus
agent
follow
adenoviru
influenza
bviru
howev
sinc
serolog
use
mani
viral
bacteri
organ
could
found
figur
confirm
anoth
studi
use
serolog
pcr
found
cap
case
caus
atyp
pathogen
addit
staphylococcu
aureu
gramneg
bacilli
klebsiella
pneumonia
nontyphoid
salmonella
spp
mycobacterium
tuberculosi
involv
etiolog
acut
pneumonia
lmic
influenzaassoci
sever
aureu
coinfect
seem
increas
recent
also
highincom
countri
almost
studi
outpati
set
perform
lmic
use
whodefinit
tabl
major
limit
generaliz
result
set
therefor
studi
lmic
industri
countri
separ
describ
nonsever
pneumonia
oral
cotrimoxazol
normal
dose
amoxicillin
tid
seem
equival
failur
rate
howev
primari
endpoint
clearli
describ
sever
pneumonia
amoxicillin
seem
superior
cotrimoxazol
shown
prospect
blind
studi
show
failur
versu
failur
respect
studi
children
bacteriaem
hib
account
bacteriaemia
sp
amoxicillin
success
children
sp
bacteriaemia
wherea
cotrimoxazol
fail
children
sp
bacteraemia
pakistan
twice
daili
oral
cotrimoxazol
prospect
blindli
compar
twice
daili
oral
amoxicillin
mgkgd
children
nonsever
pneumonia
endpoint
defin
normal
breath
rate
age
day
antibiot
equal
effect
also
high
failur
rate
vs
respect
larg
children
prospect
pakistani
studi
preschool
children
sever
pneumonia
dose
cotrimoxazol
follow
referr
inject
penicillin
guidelin
inferior
day
highdos
oral
amoxicillin
cours
bd
gener
evid
lowqual
primari
endpoint
treatment
failur
day
failur
rate
amoxicillin
group
control
group
howev
question
whether
followup
adequ
addit
mani
children
control
group
receiv
inject
penicillin
gambia
cours
cotrimoxazol
singl
penicillin
inject
follow
cours
oral
ampicillin
unknown
dose
young
children
sever
pneumonia
studi
clinic
recoveri
week
compar
treatment
arm
interestingli
prospect
doubleblind
studi
compar
oral
normal
dose
amoxicillin
cours
placebo
young
pakistani
children
nonsever
pneumonia
show
differ
therapi
failur
h
vs
p
highlight
mostli
viral
natur
lower
respiratori
infect
young
children
importantli
difficulti
breath
fever
identifi
risk
factor
failur
day
indian
prospect
doubleblind
studi
young
children
nonsever
pneumonia
wheez
persist
tachypnea
bronchodil
nebul
studi
lowto
normal
dose
oral
amoxicillin
vs
placebo
clinic
failur
defin
sever
sever
pneumonia
oxygen
satur
day
fever
persist
nonsever
pneumonia
day
observ
placebo
group
amoxicillin
group
p
number
need
treat
almost
studi
etiolog
investig
lmic
studi
inpati
set
nonblind
studi
compar
iv
vs
oral
regimen
sever
lmic
countri
show
equival
normal
dose
oral
amoxicillin
tid
inject
penicillin
children
year
sever
pneumonia
outcom
treatment
failur
lower
chest
indraw
h
group
age
younger
month
hypoxia
predict
treatment
failur
nasopharyng
wash
show
rsv
posit
group
sp
hib
colon
rsvisol
associ
treatment
failur
howev
probabl
pneumonia
caus
detect
bacteria
sp
hib
resist
amoxicillin
sinc
nasopharyng
wash
analyz
also
high
dose
amoxicillin
use
describ
whether
resist
organ
predict
treatment
failur
prospect
studi
compar
high
dose
oral
amoxicillin
cours
bd
vs
day
iv
ampicillin
follow
day
high
dose
amoxicillin
sever
pneumonia
preschool
children
primari
endpoint
treatment
failur
day
vs
respect
risk
differ
ci
posit
urin
antibacteri
activ
test
posit
test
patient
small
prospect
nonblind
pakistani
studi
hospit
children
pneumonia
oral
amoxicillin
dose
unknown
found
equal
effect
clarithromycin
oral
cefuroxim
primari
outcom
clinic
improv
h
costeffect
prospect
open
label
spear
studi
show
superior
day
iv
ampicillingentamicin
compar
iv
chloramphenicol
preschool
children
sever
pneumonia
strikingli
aureu
often
cultur
sp
open
label
trial
young
papoean
children
compar
regimen
signific
differ
observ
primari
outcom
advers
outcom
within
day
vs
advers
outcom
defin
death
treatment
failur
requir
chang
antibiot
readmiss
sever
pneumonia
within
month
discharg
abscond
hospit
note
area
high
penicillin
resist
commonli
isol
bacteria
pseudomona
aeruginosa
aureu
hib
enterobact
spp
sp
streptococcu
spp
enter
gramneg
bacilli
studi
highincom
countri
antimicrobi
manag
whodefin
nonsever
pneumonia
found
nonblind
studi
compar
day
unknown
dose
oral
amoxicillin
amoxicillinclavulan
acid
children
clinic
cap
show
superior
amoxicillinclavulan
acid
howev
endpoint
unclear
confid
interv
broad
small
studi
compar
dose
inject
penicillin
normal
oral
dose
amoxicillin
mgkgd
tid
children
rccap
find
differ
fever
respiratori
rate
gener
appear
score
h
retrospect
cohort
studi
show
betalactam
monotherapi
unknown
dose
good
macrolid
monotherapi
clinic
cap
children
year
old
irrespect
age
primari
outcom
treatment
failur
within
day
lead
prescript
new
antibiot
earlier
author
conclud
children
year
cap
might
benefit
combin
betalactam
macrolid
therapi
lead
lower
odd
treatment
failur
day
day
also
data
deriv
retrospect
studi
etiolog
studi
studi
also
describ
equal
clinic
effect
children
compar
macrolid
vs
amoxicillin
amoxicillinclavulan
acid
rccap
studi
poorli
design
probabl
influenc
pharmaceut
sponsor
role
macrolid
antibiot
hospit
children
cap
unclear
retrospect
studi
compar
ceftriaxon
macrolid
versu
ceftriaxon
monotherapi
suggest
combin
therapi
decreas
length
stay
patient
year
rr
howev
number
need
treat
result
child
hospit
length
stay
less
day
children
possibl
costeffect
etiolog
estim
fluoroquinolon
hardli
studi
children
multisit
open
noninferior
studi
children
year
old
rccap
compar
levofloxacin
broadspectrum
betalactam
therapi
year
clarithromycin
ceftriaxonemacrolid
combin
therapi
year
major
studi
group
receiv
levofloxacin
day
vs
patient
clinic
cure
rate
ident
group
serolog
sputum
analysi
perform
subject
show
pneumonia
major
pathogen
age
group
viral
caus
investig
clinic
outcom
children
year
hospit
cap
ident
narrow
ampicillinpenicillin
broadspectrum
gener
cephalosporin
iv
antibiot
accord
larg
retrospect
seri
primari
outcom
sever
clinic
paramet
day
iv
treatment
day
oxygen
requir
day
hospit
readmiss
rate
confirm
prospect
random
observ
studi
pediatr
patient
proven
lobar
pneumonia
look
clinic
laboratori
radiolog
outcom
penicillin
vs
cefuroxim
exampl
pivot
trial
prospect
compar
low
dose
oral
amoxicillin
mgkgd
tid
iv
penicillin
follow
low
dose
oral
amoxicillin
children
hospit
rccap
month
old
unit
kingdom
oral
amoxicillin
clinic
equival
iv
penicillin
regard
time
resolut
fever
hypoxia
oral
intervent
costeffect
howev
children
sever
pneumonia
exclud
nasoand
oropharyng
swab
taken
viral
pcr
result
describ
children
sever
pneumonia
iv
oxacillinceftriaxon
combin
therapi
prospect
compar
iv
amoxicillinclavulan
acid
monotherapi
normal
dose
amoxicillinclavulan
acid
group
significantli
better
respect
tachypnoea
improv
hospit
length
stay
latter
probabl
fulli
explain
fact
iv
amoxicillinclavulan
acid
switch
oral
amoxicillinclavulan
acid
h
case
improv
data
short
day
versu
longer
cours
iv
antibiot
day
preschool
children
sever
pneumonia
preschool
outpati
rccap
cours
high
dose
amoxicillin
mgkgd
tid
inferior
cours
cours
associ
unaccept
failur
rate
prospect
studi
countri
high
penicillin
resist
nonsever
pneumonia
underf
short
cours
day
antibiot
seem
effect
long
cours
day
base
prospect
studi
lmic
howev
whodefinit
pneumonia
use
studi
therefor
mani
children
viral
infect
might
includ
underf
rccap
region
low
pneumococc
penicillin
resist
oral
amoxicillin
mgkgday
bd
efficaci
tid
dose
result
must
interpret
caution
imposs
distinguish
viral
bacteri
pneumonia
chest
radiograph
twice
daili
normal
dose
amoxicillin
also
use
compar
studi
amoxicillin
cotrimoxazol
pharmacokinet
studi
compar
bd
tid
dose
mgkgd
amoxicillin
young
children
conclud
time
mic
probabl
insuffici
higher
concentr
level
therefor
mgkgd
dose
consid
bd
dose
standard
doubl
strength
cotrimoxazol
equal
effect
treat
nonsever
pneumonia
treatment
failur
group
h
absenc
differ
high
treatment
failur
might
relat
viral
etiolog
nonsever
pneumonia
role
system
corticosteroid
pediatr
cap
far
clear
two
retrospect
studi
describ
associ
prolong
hospit
stay
greater
odd
rehospit
case
cap
without
wheez
asthma
children
sever
pneumonia
icuset
methylprednisolon
cours
imipenem
led
faster
resolut
symptom
compar
imipenem
alon
trial
small
blind
till
system
corticosteroid
recommend
pediatr
cap
without
wheez
anecdot
report
describ
fast
improv
ad
steroid
sever
pneumococc
cap
retrospect
proven
benefit
oseltamivir
hospit
pediatr
patient
without
underli
diseas
risk
factor
develop
seriou
ill
includ
asthma
also
cochran
metaanalysi
mainli
base
poorli
design
studi
describ
signific
benefit
oseltamivir
treatment
children
pneumonia
although
might
reduc
symptom
earlier
without
clinic
relev
welldesign
studi
need
studi
role
oseltamivir
influenza
pneumonia
previous
healthi
children
hospit
cap
oral
antibiot
treatment
broadspectrum
show
better
outcom
compar
narrowspectrum
therapi
retrospect
studi
prospect
studi
need
appropri
recommend
trial
describ
whether
includ
children
vaccin
hib
betalactamas
product
hib
may
vari
per
region
accord
local
resist
pattern
decid
add
betalactamas
inhibitor
prescrib
gener
cephalosporin
prolong
antimicrobi
therapi
warrant
irrespect
addit
treatment
modal
videoassist
thoracoscop
surgeri
vat
fibrinolysi
retrospect
studi
compar
outpati
iv
versu
oral
treatment
show
differ
outcom
thu
promot
oral
treatment
confirm
anoth
retrospect
cohort
studi
evalu
children
empyema
treatment
failur
rate
ident
group
picc
oral
current
evid
recommend
specif
antimicrobi
therapi
major
thorac
empyema
caus
sp
notabl
serotyp
follow
aureu
antibiot
choic
direct
cultur
pcr
narrow
possibl
case
sp
aureu
addit
clindamycin
rifampicin
mention
durat
suggest
rang
continu
antibiot
day
resolut
fever
till
extend
antibiot
cours
week
discharg
incomplet
knowledg
optim
treatment
cap
defin
fact
etiolog
difficult
establish
often
multifactori
viral
bacteri
pulmonari
sampl
hard
obtain
therefor
surrog
marker
upper
respiratori
tract
often
use
avail
etiolog
studi
incompar
differ
sampl
method
laboratori
techniqu
definit
pneumonia
among
studi
summar
studi
seem
bacteri
etiolog
probabl
except
studi
honkinen
detect
bacteria
induc
sputum
hospit
children
cultur
pcr
studi
pavia
nasopharyng
bacteria
cultur
major
children
honkinen
studi
sputum
aspir
trough
nostril
probabl
also
retriev
nasopharyng
pathogen
posit
predict
valu
nasopharyng
bacteri
pathogen
reflect
lower
respiratori
tract
pathogen
optim
therefor
conclud
whether
nasopharyng
pathogen
colon
respiratori
tract
also
pneumoniacaus
pathogen
etiolog
studi
investig
clinic
capcas
might
therefor
repres
nonsever
cap
hospit
level
higher
chanc
bacteri
caus
cap
compar
commun
level
clear
virus
play
import
role
major
childhood
cap
especi
underf
virus
mainli
rsv
hrv
influenza
seem
play
import
role
sever
cap
might
even
play
import
role
nonsever
cap
howev
respiratori
virus
also
detect
upper
respiratori
tract
healthi
children
less
frequenc
compar
case
therapeut
studi
differ
set
dose
outcom
diagnosi
rc
vs
whodefinit
moreov
resist
rate
highli
divers
account
valid
generaliz
mani
trial
low
composit
endpoint
use
mani
trial
treatment
failur
etiolog
often
extens
studi
might
lead
valid
threat
also
trial
compar
iv
vs
oral
regimen
blind
ethic
issu
larg
lmic
studi
antimicrobi
pretreat
often
adjust
howev
probabl
import
contributor
treatment
failur
larg
studi
deriv
lmic
probabl
repres
develop
countri
simpli
whoalgorithm
use
pneumonia
local
level
health
servic
use
develop
set
treatment
failur
rate
divers
strikingli
nonsever
pneumonia
failur
rate
averag
lower
compar
sever
pneumonia
stress
fact
etiolog
might
nonbacteri
failur
rate
specif
criteria
rccap
low
ad
fever
criteria
improv
specif
substanti
small
reduct
sensit
commun
rural
level
criteria
use
identifi
child
risk
possibl
need
livesav
treatment
industri
citi
set
experi
diagnost
avail
establish
sever
clinic
pneumonia
unfortun
rapid
reliabl
test
distinguish
viralfrom
bacteri
pneumonia
still
lack
set
treatment
fulli
ration
decis
rule
current
explor
decreas
number
children
prescrib
antibiot
case
probabl
viral
cap
person
commun
young
children
cough
fast
breath
without
fever
justifi
antibiot
watch
wait
return
visit
suggest
imposs
distinguish
pneumonia
bronchiol
viral
wheez
base
criteria
alon
case
clinic
sever
pneumonia
fever
rccap
oral
amoxicillin
proven
effect
major
children
equival
superior
compar
cotrimoxazol
oral
amoxicillin
equival
iv
narrowspectrum
betalactam
iv
narrowspectrum
betalactam
treatment
inferior
broadspectrum
betalactam
antibiot
dose
amoxicillin
use
cite
studi
vari
therefor
difficult
compar
whether
clinic
effect
depend
dose
normal
dose
mgkgd
tid
would
suffici
set
low
level
penicillin
resist
bd
dose
question
failur
patient
reach
concentr
mic
time
case
highlevel
penicillin
resist
bd
dose
prefer
durat
probabl
uncompl
bacteri
pneumonia
extend
day
base
small
studi
macrolid
antibiot
inferior
betalactam
antibiot
also
proven
superior
even
older
children
addit
betalactam
macrolid
combin
therapi
never
shown
clearli
benefici
lack
good
studi
rapid
develop
macrolid
resist
smallspectrum
betalactam
antibiot
prefer
case
cap
reason
initi
second
third
gener
cephalosporin
treatment
uncompl
cap
vaccin
child
without
recent
pretreat
might
indic
case
suspect
gramneg
aureu
influenza
infect
sever
pneumonia
children
previou
medic
histori
hardli
evid
adjunct
therapi
childhood
cap
optim
antimicrobi
manag
childhood
cap
depend
etiolog
age
local
vaccin
polici
resist
pattern
long
nonrapid
surrog
marker
use
distinguish
viralfrom
bacteri
pneumonia
manag
probabl
suboptim
young
child
sign
nonsever
pneumonia
without
wheez
otherwis
well
watch
wait
would
recommend
probabl
viral
etiolog
children
sever
cap
fever
oral
amoxicillin
narrowspectrum
iv
betalactam
therapi
would
first
choic
clear
evid
superior
macrolidebas
regimen
age
five
day
enough
treat
uncompl
pneumonia
dosag
depend
local
penicillin
resist
rate
broadspectrum
therapi
cover
betalactamas
produc
bacteria
warrant
case
sever
diseas
pretreat
children
author
support
grant
espid
sticht
coolsingel
zonmw
sponsor
involv
collect
analysi
interpret
data
write
manuscript
articl
contain
studi
human
particip
perform
author
creat
decis
algorithm
help
doctor
ration
prescrib
antibiot
cap
develop
rapid
marker
includ
transcriptom
distinguish
viral
bacteri
etiolog
childhood
cap
identifi
patient
might
benefit
addon
macrolid
therapi
